Dividend Kings: Stability and Growth Combined
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy ABBV?
Source: Fool
- Dividend Growth Stability: Currently, 57 stocks hold the title of Dividend Kings, with American States Water increasing its dividend for 71 consecutive years, demonstrating long-term stability and commitment to shareholders, which attracts investors seeking passive income.
- AbbVie's Revenue Growth: AbbVie reported $5 billion and $2.37 billion in revenue from its new drugs Skyrizi and Rinvoq in Q4 2025, reflecting a 32% and 29.5% increase year-over-year, respectively, providing strong support for the company's revenue transition after losing Humira's exclusivity.
- Walmart's E-commerce Growth: Walmart's U.S. e-commerce sales surged 27% in Q1 2025, with international sales up 17%, and despite a modest 0.8% dividend yield, its 46% stock price increase and 53 consecutive years of dividend growth bolster investor confidence.
- Con Edison Capital Expenditure Plans: Con Edison plans to invest $6.6 billion in 2025 and $6.8 billion in 2026 on capital projects aimed at upgrading transmission lines and modernizing gas systems, which is expected to drive stable long-term returns and meet the growing energy demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 203.710
Low
223.00
Averages
252.00
High
289.00
Current: 203.710
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Ratings Overview
- Cybersecurity Investment Opportunity: Berenberg initiates coverage on Palo Alto Networks with a buy rating, highlighting its status as a 'best-in-class' player in cybersecurity, combining multiple growth engines and strong product breadth, which is expected to attract more investor interest in its sustained growth potential.
- Optimistic Tesla Outlook: Bank of America reiterates Tesla as a buy, anticipating that the upcoming Q1 earnings report will focus on its robotaxi deployments aimed at disrupting the rideshare market and capturing a portion of the $1 trillion market opportunity, showcasing its strategic advantage amid increasing competition.
- Packaging Industry Growth Potential: Raymond James upgrades Ball Corp to outperform, citing the company's strong performance in cost pass-throughs and structural support for the beverage sector, predicting it will achieve outsized growth compared to its packaging peers.
- Biopharma Market Prospects: Canaccord initiates AbbVie with a buy rating and a price target of $262, emphasizing its position as a 'core holding' and showcasing its strong growth potential and market appeal in the biopharmaceutical sector.
See More
Apple's New CEO Takes Over Amid Optimistic Market Outlook
- Apple Leadership Change: Apple announced that Senior Vice President of Hardware Engineering John Ternus will take over as CEO on September 1, succeeding Tim Cook, who has led the company to a market cap increase of over 20 times to $4 trillion since 2011, presenting Ternus with significant leadership challenges.
- UnitedHealth Earnings Beat: UnitedHealth reported strong quarterly results with a medical benefit ratio of 83.9%, better than the 85.5% consensus, leading to a more than 7% increase in shares, alongside a plan to buy back at least $2 billion in stock by Q2, indicating robust financial health.
- GE Aerospace Performance: GE Aerospace's quarterly results exceeded expectations with orders rising 87% to $23 billion and revenue increasing 25% to $12.39 billion, and despite travel issues in Asia and the U.S., management maintained prior guidance, reflecting ongoing improvements in the defense sector.
- Amazon's Increased Investment: Amazon is boosting its investment in AI company Anthropic by an additional $5 billion, with an option for $20 billion more upon achieving commercial milestones, aiming to reduce reliance on Nvidia and address the growing demand for computing power, showcasing Amazon's strategic positioning in the AI landscape.
See More
Pfizer Accelerates Catch-Up in Weight Loss Drug Market
- Increased Market Competition: Pfizer's PF-08653944 shows a weight loss of 10% to 12% in Phase 2b trials, and while its efficacy is similar to Novo Nordisk's Wegovy and Eli Lilly's Zepbound, its monthly injection regimen could make it a more appealing option, thereby putting pressure on the existing market.
- Sales Fluctuations: Novo Nordisk's Wegovy saw an increase in total prescriptions for 2025, yet it declined before year-end, with expectations of a 5% to 13% drop in revenue due to weakness in its weight-loss drug business, highlighting the market's sensitivity to pricing.
- Significant Growth for Eli Lilly: Eli Lilly's Zepbound achieved a remarkable 175% revenue growth last year, rising from $4.9 billion to $13.5 billion, although its growth rate began to slow in Q4, reflecting the impact of intensified market competition.
- Uncertain Future Outlook: Pfizer plans over 20 anti-obesity trials in 2026, including 10 Phase 3 trials for PF-08653944; while still in early stages, successful trials could reshape the GLP-1 drug market landscape, increasing pressure on Novo Nordisk and Eli Lilly.
See More
Pfizer Drug Poised to Disrupt Weight Loss Market
- Increased Market Competition: The dominance of Novo Nordisk and Eli Lilly in the weight loss drug market is threatened as Pfizer's PF-08653944 shows a weight loss of 10% to 12% in Phase 2 trials, potentially altering existing pricing power.
- Dosing Advantage: Pfizer's PF-08653944 requires only monthly injections, unlike Novo's Wegovy and Lilly's Zepbound, which necessitate weekly doses; this dosing difference could attract more patients and impact market share.
- Revenue Outlook Decline: Novo Nordisk anticipates a revenue drop of 5% to 13% in 2025 due to increased competition and pricing pressures, particularly with Pfizer's drug poised for market entry.
- Future Trial Plans: Pfizer plans over 20 anti-obesity trials in 2026, including 10 Phase 3 trials for PF-08653944, which could further intensify market competition and compress profit margins.
See More
California's Antitrust Case Against Amazon Unveils New Evidence
- New Evidence in Antitrust Case: California's Attorney General released documents revealing internal communications between Amazon and major vendors, indicating alleged coercion to raise prices at rival retailers like Walmart and Target, thereby stifling competition and impacting consumer pricing.
- Price Manipulation Allegations: Amazon is accused of pressuring brands such as Levi Strauss and Hanes to inflate prices on competing platforms, resulting in higher costs for consumers across multiple sites and further entrenching its dominant market position.
- Legal Action Request: The Attorney General's office has requested the court to prohibit Amazon from continuing these alleged price-fixing practices and to appoint an independent monitor to ensure compliance, reflecting serious concerns over Amazon's market behavior.
- Market Share Impact: With Amazon controlling up to 50% of the U.S. e-commerce market, its pricing strategies are seen as a primary factor driving up prices for competitors, potentially leading to significant implications for future market dynamics and consumer choices.
See More
Amazon Accused of Price Fixing in Antitrust Case
- Price Fixing Allegations: California Attorney General accuses Amazon of pressuring major brands like Levi Strauss and Hanes to inflate prices on competing platforms, resulting in higher costs for consumers and highlighting Amazon's dominant position in the e-commerce market.
- Antitrust Lawsuit Developments: Newly unsealed documents reveal communications between Amazon and Hanes, where Hanes confirmed reaching out to Target and Walmart to raise prices, indicating Amazon's pressure tactics to maintain profit margins in a competitive landscape.
- Market Share Impact: With Amazon controlling approximately 50% of the U.S. e-commerce market, the Attorney General asserts that such practices not only harm competition but also lead to increased consumer prices, reflecting Amazon's stronghold in the industry.
- Expected Legal Consequences: The Attorney General has requested the court to prohibit Amazon from continuing these alleged price-fixing practices during the lawsuit and to appoint an independent monitor for compliance, with the case set to go to trial in 2027, potentially impacting Amazon's operational model significantly.
See More
Latest Wall Street Ratings Overview
- Cybersecurity Investment Opportunity: Berenberg initiates coverage on Palo Alto Networks with a buy rating, highlighting its status as a 'best-in-class' player in cybersecurity, combining multiple growth engines and strong product breadth, which is expected to attract more investor interest in its sustained growth potential.
- Optimistic Tesla Outlook: Bank of America reiterates Tesla as a buy, anticipating that the upcoming Q1 earnings report will focus on its robotaxi deployments aimed at disrupting the rideshare market and capturing a portion of the $1 trillion market opportunity, showcasing its strategic advantage amid increasing competition.
- Packaging Industry Growth Potential: Raymond James upgrades Ball Corp to outperform, citing the company's strong performance in cost pass-throughs and structural support for the beverage sector, predicting it will achieve outsized growth compared to its packaging peers.
- Biopharma Market Prospects: Canaccord initiates AbbVie with a buy rating and a price target of $262, emphasizing its position as a 'core holding' and showcasing its strong growth potential and market appeal in the biopharmaceutical sector.
See More
Apple's New CEO Takes Over Amid Optimistic Market Outlook
- Apple Leadership Change: Apple announced that Senior Vice President of Hardware Engineering John Ternus will take over as CEO on September 1, succeeding Tim Cook, who has led the company to a market cap increase of over 20 times to $4 trillion since 2011, presenting Ternus with significant leadership challenges.
- UnitedHealth Earnings Beat: UnitedHealth reported strong quarterly results with a medical benefit ratio of 83.9%, better than the 85.5% consensus, leading to a more than 7% increase in shares, alongside a plan to buy back at least $2 billion in stock by Q2, indicating robust financial health.
- GE Aerospace Performance: GE Aerospace's quarterly results exceeded expectations with orders rising 87% to $23 billion and revenue increasing 25% to $12.39 billion, and despite travel issues in Asia and the U.S., management maintained prior guidance, reflecting ongoing improvements in the defense sector.
- Amazon's Increased Investment: Amazon is boosting its investment in AI company Anthropic by an additional $5 billion, with an option for $20 billion more upon achieving commercial milestones, aiming to reduce reliance on Nvidia and address the growing demand for computing power, showcasing Amazon's strategic positioning in the AI landscape.
See More
Pfizer Accelerates Catch-Up in Weight Loss Drug Market
- Increased Market Competition: Pfizer's PF-08653944 shows a weight loss of 10% to 12% in Phase 2b trials, and while its efficacy is similar to Novo Nordisk's Wegovy and Eli Lilly's Zepbound, its monthly injection regimen could make it a more appealing option, thereby putting pressure on the existing market.
- Sales Fluctuations: Novo Nordisk's Wegovy saw an increase in total prescriptions for 2025, yet it declined before year-end, with expectations of a 5% to 13% drop in revenue due to weakness in its weight-loss drug business, highlighting the market's sensitivity to pricing.
- Significant Growth for Eli Lilly: Eli Lilly's Zepbound achieved a remarkable 175% revenue growth last year, rising from $4.9 billion to $13.5 billion, although its growth rate began to slow in Q4, reflecting the impact of intensified market competition.
- Uncertain Future Outlook: Pfizer plans over 20 anti-obesity trials in 2026, including 10 Phase 3 trials for PF-08653944; while still in early stages, successful trials could reshape the GLP-1 drug market landscape, increasing pressure on Novo Nordisk and Eli Lilly.
See More
Pfizer Drug Poised to Disrupt Weight Loss Market
- Increased Market Competition: The dominance of Novo Nordisk and Eli Lilly in the weight loss drug market is threatened as Pfizer's PF-08653944 shows a weight loss of 10% to 12% in Phase 2 trials, potentially altering existing pricing power.
- Dosing Advantage: Pfizer's PF-08653944 requires only monthly injections, unlike Novo's Wegovy and Lilly's Zepbound, which necessitate weekly doses; this dosing difference could attract more patients and impact market share.
- Revenue Outlook Decline: Novo Nordisk anticipates a revenue drop of 5% to 13% in 2025 due to increased competition and pricing pressures, particularly with Pfizer's drug poised for market entry.
- Future Trial Plans: Pfizer plans over 20 anti-obesity trials in 2026, including 10 Phase 3 trials for PF-08653944, which could further intensify market competition and compress profit margins.
See More
California's Antitrust Case Against Amazon Unveils New Evidence
- New Evidence in Antitrust Case: California's Attorney General released documents revealing internal communications between Amazon and major vendors, indicating alleged coercion to raise prices at rival retailers like Walmart and Target, thereby stifling competition and impacting consumer pricing.
- Price Manipulation Allegations: Amazon is accused of pressuring brands such as Levi Strauss and Hanes to inflate prices on competing platforms, resulting in higher costs for consumers across multiple sites and further entrenching its dominant market position.
- Legal Action Request: The Attorney General's office has requested the court to prohibit Amazon from continuing these alleged price-fixing practices and to appoint an independent monitor to ensure compliance, reflecting serious concerns over Amazon's market behavior.
- Market Share Impact: With Amazon controlling up to 50% of the U.S. e-commerce market, its pricing strategies are seen as a primary factor driving up prices for competitors, potentially leading to significant implications for future market dynamics and consumer choices.
See More
Amazon Accused of Price Fixing in Antitrust Case
- Price Fixing Allegations: California Attorney General accuses Amazon of pressuring major brands like Levi Strauss and Hanes to inflate prices on competing platforms, resulting in higher costs for consumers and highlighting Amazon's dominant position in the e-commerce market.
- Antitrust Lawsuit Developments: Newly unsealed documents reveal communications between Amazon and Hanes, where Hanes confirmed reaching out to Target and Walmart to raise prices, indicating Amazon's pressure tactics to maintain profit margins in a competitive landscape.
- Market Share Impact: With Amazon controlling approximately 50% of the U.S. e-commerce market, the Attorney General asserts that such practices not only harm competition but also lead to increased consumer prices, reflecting Amazon's stronghold in the industry.
- Expected Legal Consequences: The Attorney General has requested the court to prohibit Amazon from continuing these alleged price-fixing practices during the lawsuit and to appoint an independent monitor for compliance, with the case set to go to trial in 2027, potentially impacting Amazon's operational model significantly.
See More
